Business
Anticipated new collaboration with Diatech
Anticipated new collaboration with Diatech.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 4156J Physiomics PLC 12 June 2014 \n \n\nPhysiomics plc\n(\"Physiomics\") or (\"the Company\")\nPhysiomics enters the personalized medicine market. Anticipated new collaboration with Diatech Pharmacogenetics\n \nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a Heads of Terms agreement with Diatech Pharmacogenetics srl (\"Diatech\") to negotiate a Collaboration Agreement. Under the terms of the anticipated Collaboration Agreement Physiomics and Diatech will develop an innovative in-silico platform to personalize cancer patient treatment.\n \nThis anticipated new in-silico platform will combine pharmacological information related to cancer drugs with genomic and physiological information about the patient, to predict which treatments and regimens are likely to lead to an increase in survival. The platform will initially be used to support physicians to make the best choice of available treatment options for patients. Ultimately, the software could be further developed to choose the right patient groups for clinical trials of new drugs. \n \nThe parties anticipate signing a full collaboration agreement within 6 months and a further announcement will be made at that time if it is executed.\n \nDiatech is the market leader for cancer Pharmacogenetics in Italy with a 80% market share into the CE IVD segment. They would provide the necessary clinical calibration via an existing network of cancer centres. If completed, the directors believe the collaboration would provide a direct route to market for Italy and potentially other Diatech clients in Europe, where the software developed could be sold in combination with Diatech's kits.\n \n \nMr Fabio Biondi, President of Diatech, commented:\n\"This collaboration could open up new frontiers for clinical research and medicine. We are excited to be progressing this anticipated new project among the list of research activities that we are conducting into the personalized medicine field. We are also confident that this co-development could add new interesting products into our portfolio. We believe that this new tool could enhance the capability of our customers to identify the best personalized therapy for the patients and therefore improve the quality of ...